Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: nivolumab Clear all
Terminated Phase 1 Interventional

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

NCT03906526
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
VTX-2337, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ACY-241, nivolumab, ipilimumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

NCT03695250
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
IDO1 Inhibitor BMS-986205, Nivolumab
Drug · Biological
Lead sponsor
Edward Kim
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

NCT03604978
View directory record Official record
Conditions
Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions
Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

NCT03525925
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 23, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

NCT03223155
View directory record Official record
Conditions
Stage IV Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

NCT03544723
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
Ad-p53
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 9:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

NCT03646461
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
342
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

NCT03651271
View directory record Official record
Conditions
Advanced Metastatic Cancer, Advanced Prostate Cancer
Interventions
Nivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer, Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer
Biological
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

NCT05199285
View directory record Official record
Conditions
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Ipilimumab, Nivolumab
Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Results available

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

NCT03181308
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Carotuximab (TRC105), OPDIVO
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

NCT03572478
View directory record Official record
Conditions
Prostate Cancer, Endometrial Cancer
Interventions
Rucaparib, Nivolumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 23, 2026, 9:03 PM EDT
Enrolling by invitation No phase listed Observational

Development and Analysis of a Stool Bank for Cancer Patients

NCT04291755
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Interventions
Pembrolizumab Injection
Drug
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Fountain Valley, California • Winter Haven, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177
View directory record Official record
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

NCT04039607
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Ipilimumab, Sorafenib, lenvatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
15
States / cities
Tucson, Arizona • Coronado, California • Duarte, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT04047706
View directory record Official record
Conditions
Glioblastoma
Interventions
IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy, Temozolomide, IDO1 Inhibitor BMS-986205 50 mg, IDO1 Inhibitor BMS-986205 100 mg
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

NCT05317000
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Combination 5-azacytidine and nivolumab, Nivolumab
Drug
Lead sponsor
Barbara Burtness
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

NCT06675643
View directory record Official record
Conditions
Malignant Skin Neoplasm, Melanoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
Drug · Other · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

NCT03439891
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Nivolumab, Sorafenib
Biological · Drug
Lead sponsor
Robin Kate Kelley
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Not listed Phase 2 Interventional

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

NCT05223816
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions
VG161, Nivolumab Injection [Opdivo]
Drug
Lead sponsor
Virogin Biotech Canada Ltd
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 23, 2026, 9:03 PM EDT